NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC

Sichuan Kelun-Biotech announced regulatory acceptance of a new indication application for sacituzumab tirumotecan (sac-TMT/SKB264), a TROP2-directed antibody-drug conjugate co-developed with Merck, in China's NMPA review process. This represents the sixth approved indication pathway for the therapeutic candidate, targeting first-line treatment of recurrent or metastatic triple-negative breast cancer (TNBC) in PD-L1-positive patient populations.

The regulatory milestone signals continued clinical validation and commercial expansion potential for this ADC platform in one of the world's largest pharmaceutical markets. China's NMPA acceptance of a first-line oncology indication—historically reserved for proven efficacy profiles—reflects confidence in preliminary efficacy data. TNBC represents a significant unmet medical need given its aggressive phenotype and limited treatment options compared to hormone-receptor-positive variants.

For Merck, this application reinforces its oncology portfolio diversification and validates the ADC mechanism in early-treatment settings where efficacy thresholds are higher. Kelun-Biotech's ability to advance multiple indications within the Chinese regulatory framework demonstrates operational execution and intellectual property strength, though this remains a mid-stage development milestone rather than a commercial authorization.

Sector implication: Health Care gains modest positive signal from oncology pipeline advancement. The news carries limited broad-market correlation given geographic concentration (China) and pre-commercial stage, though it supports longer-term bullish sentiment for precision oncology and ADC therapies within specialized biotech and large-cap pharma segments.